Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ASEP Medical HoldingsSEPSF 19 Cash Ratio is 0.05 as of Mar. 2026, which is 69% below its 10-year median of 0.16. GuruFocus rates SEPSF with a GF Score™ of 19/100. The stock has 4 warning signs investors should review. Among 1,381 Biotechnology companies, ASEP Medical Holdings ranks worse than 96.74% on this metric.
ASEP Medical Holdings has a Cash Ratio of 0.05. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.
The historical rank and industry rank for ASEP Medical Holdings's Cash Ratio or its related term are showing as below:
SEPSF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.01 Med: 0.16 Max: 54.33
Current: 0.05
During the past 5 years, ASEP Medical Holdings's highest Cash Ratio was 54.33. The lowest was 0.01. And the median was 0.16.
SEPSF's Cash Ratio is ranked worse than 96.74% of 1381
companies
in the Biotechnology industry
Industry Median: 2.95
vs SEPSF: 0.05
ASEP Medical Holdings (OTCPK:SEPSF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ASEP Medical Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ASEP Medical Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ASEP Medical Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where ASEP Medical Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASEP Medical Holdings (SEPSF) has a Cash Ratio of 0.05 as of Mar. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ASEP Medical Holdings and its competitors. This is 69% below median its historical median of 0.16. Over the past decade, ASEP Medical Holdings' Cash Ratio has ranged from 0.01 to 54.33. According to the industry distribution chart, ASEP Medical Holdings ranks #1336 out of 1381 companies in the Biotechnology industry, placing it in the top 96.7%.
Is ASEP Medical Holdings' Cash Ratio too high?
ASEP Medical Holdings' current Cash Ratio of 0.05 is 69% below median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 54.33. The Biotechnology industry median Cash Ratio is 2.95. ASEP Medical Holdings' value of 0.05 is 98.3% below this industry median. Based on the distribution chart, ASEP Medical Holdings ranks #1336 out of 1381 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ASEP Medical Holdings has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does ASEP Medical Holdings' Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ASEP Medical Holdings ranks #1336 out of 1381 companies for Cash Ratio. This places ASEP Medical Holdings in the lower half of its industry. The industry median Cash Ratio is 2.95. ASEP Medical Holdings' value of 0.05 is 98.3% below this benchmark. Historically, ASEP Medical Holdings' own Cash Ratio has ranged from 0.01 to 54.33 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 2.95, ASEP Medical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ASEP Medical Holdings's current Cash Ratio of 0.05 is 98.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on ASEP Medical Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ASEP Medical Holdings's current Cash Ratio is 0.05, which is 69% below median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ASEP Medical Holdings stock overvalued right now?
ASEP Medical Holdings (SEPSF) has a current Cash Ratio of 0.05. The current Cash Ratio is 0.05, which is 69% below median its 10-year median of 0.16 and 98.3% below the Biotechnology industry median of 2.95. ASEP Medical Holdings' overall GF Score™ is 19/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For ASEP Medical Holdings (SEPSF), the current Cash Ratio is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ASEP Medical Holdings Inc is in the business of acquiring research and development assets, technologies and/or businesses in the area of life sciences and medical diagnostics. Diagnostic and therapeutic solutions represent tremendous clinical and commercial potential, through rapid diagnostics and uniquely effective treatments. Its Diagnostic has developed a novel diagnostic assay for the early and rapid risk assessment of sepsis. Therapeutic offering: Patented peptide technology targets infection-causing biofilms and reduces inflammation.
19GF Score
Get the complete analysis for SEPSF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SEPSF has been successfully added to your 
